Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Robert J Orlowski"'
Autor:
Brian Slomovitz, David Cibula, Murat Gultekin, Mansoor Mirza, Beata Maćkowiak-Matejczyk, Alexandra Taylor, Ignacio Romero, Nicoletta Colombo, Jacob Korach, Jianqing Zhu, Lucy Gilbert, Kosei Hasegawa, Jae-Weon Kim, Sally Baron-Hay, Vicky Makker, Robert L Coleman, Robert J Orlowski, Xuan Zhou, Vivek Khemka, Sandro Pignata
Publikováno v:
E-Posters (Trials In Progress).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b29036b0552c1d4c5ee0b960aebf9586
https://doi.org/10.1136/ijgc-2022-igcs.525
https://doi.org/10.1136/ijgc-2022-igcs.525
Autor:
Vicky, Makker, Nicoletta, Colombo, Antonio, Casado Herráez, Alessandro D, Santin, Emeline, Colomba, David S, Miller, Keiichi, Fujiwara, Sandro, Pignata, Sally, Baron-Hay, Isabelle, Ray-Coquard, Ronnie, Shapira-Frommer, Kimio, Ushijima, Jun, Sakata, Kan, Yonemori, Yong Man, Kim, Eva M, Guerra, Ulus A, Sanli, Mary M, McCormack, Alan D, Smith, Stephen, Keefe, Steven, Bird, Lea, Dutta, Robert J, Orlowski, Domenica, Lorusso, Lynne, Knowles
BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previousl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80bf5a23a6784e2b36d308838a72a533
http://hdl.handle.net/10281/346556
http://hdl.handle.net/10281/346556
Autor:
Felix Quagliarello, Michael D. Farwell, Lydia Giles, Lakshmi Chilukuri, Qing Zhao, Sangeeth M. George, Melanie W. Kier, Shujing Liu, Patrick Yan, Lakshmanan Annamalai, Kurt D'Andrea, Suzanne McGettigan, Kristin Kreider, Wendy M. Blumenschein, Lynn M. Schuchter, Andrew Kozlov, Robin Mogg, Robert J. Orlowski, E. John Wherry, Bradley Wubbenhorst, Bertram Bengsch, Katherine L. Nathanson, Jennifer H. Yearley, Rosemarie Mick, Sasikanth Manne, Ramin S. Herati, Xiaowei Xu, Brandon Wenz, Tara C. Mitchell, Gerald P. Linette, Liza Dorfman, Alexander C. Huang, Adam A. Kraya, Ravi K. Amaravadi, Giorgos C. Karakousis, Wei Xu, Mary Carberry
Publikováno v:
Nature Medicine. 25:454-461
Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9631070ec173070db5eae7885fbfb2c8
https://doi.org/10.1038/s41591-019-0357-y
https://doi.org/10.1038/s41591-019-0357-y
Autor:
Brian M. Slomovitz, David Cibula, Tayup Simsek, Mansoor Raza Mirza, Beata Maćkowiak-Matejczk, Emma Hudson, Ignacio Romero, Nicoletta Colombo, Jacob Korach, Rutie Yin, Lucy Gilbert, Kosei Hasegawa, Alexandra Tyulyandina, Sally E. Baron-Hay, Lyndsay Willmott, Floor Jenniskens Backes, Robert J. Orlowski, Xuan Zhou, Vivek Khemka, Sandro Pignata
Publikováno v:
Journal of Clinical Oncology. 40:TPS5623-TPS5623
TPS5623 Background: Carboplatin-paclitaxel chemotherapy (with trastuzumab for HER2+ uterine serous carcinoma) is the standard of care first-line systemic treatment for recurrent or metastatic endometrial carcinoma (EC), which has a 5-year relative su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73131dd79af329d63dbecc3dcd2076fa
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5623
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5623
Autor:
Lena Sophie Mayer, Robert J. Orlowski, Josephine Giles, Joseph L. Benci, Gavin Ellis, Guoping Deng, John Attanasio, Zeyu Chen, Bertram Bengsch, Omar Kahn, Sasikanth Manne, Ramin S. Herati, Shin Ngiow, Sangeeth M. George, Denise L. Faustman, Gary Gilliland, Rosemarie Mick, Wei Xu, Suzanne McGettigan, Xiaowei Xu, Ravi K. Amaravadi, Giorgos C. Karakousis, Lynn M. Schuchter, Tara C. Mitchell, James L. Riley, Alexander C. Huang, Andy Minn, Vesselin Tomov, E. John Wherry
Publikováno v:
The Journal of Immunology. 204:165.42-165.42
Overcoming acquired adaptive immune resistance to anti-PD-1 therapy is imperative for enhancing the efficacy of immune checkpoint blockade (ICB) in solid tumors. Regulatory T cells (Tregs) play a prominent role in the suppressive tumor microenvironme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4a3798697c07ae9611f977ab33fb83c
https://doi.org/10.4049/jimmunol.204.supp.165.42
https://doi.org/10.4049/jimmunol.204.supp.165.42
Publikováno v:
Current Opinion in Hematology. 22:97-107
Purpose of review Despite successful remission induction in 60-80% of patients with newly diagnosed acute myeloid leukemia, there remain a significant number of patients who exhibit primary refractory disease. Here we examine the data for predicting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ada33a7a1d3ad650e7d5993ba60b11
https://doi.org/10.1097/moh.0000000000000115
https://doi.org/10.1097/moh.0000000000000115
Autor:
Gareth P. Gregory, Pier L. Zinzani, John Palcza, Jane A. Healy, Robert J. Orlowski, Akash Nahar, Philippe Armand
Publikováno v:
Cancer Research. 79:CT106-CT106
Background: Most lymphomas, including classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and indolent B-cell lymphomas, are not readily curable in the relapsed/refractory (R/R) setting; new treatment options are urgently needed. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2a10932ed69c6dac4be719c5691ca37
https://doi.org/10.1158/1538-7445.am2019-ct106
https://doi.org/10.1158/1538-7445.am2019-ct106
Publikováno v:
British journal of haematology. 177(1)
The success of genetically engineered T cells that express chimeric antigen receptors (CARTs) has been a momentous step forward in harnessing the potent cancer fighting abilities of the immune system. The efficacy seen in relapsed/refractory (r/r) ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d589843ac3c93448d37d82a2cc98cf74
https://pubmed.ncbi.nlm.nih.gov/27977050
https://pubmed.ncbi.nlm.nih.gov/27977050
Autor:
Ramin S. Herati, Bradley Wubbenhorst, Jason M. Schenkel, Robert H. Vonderheide, Kurt D'Andrea, Shannon Harmon, Shawn Kothari, Felix Quagliarello, Michael A. Postow, Brandon Wenz, Katherine L. Nathanson, Ravi K. Amaravadi, Lynn M. Schuchter, Robert J. Orlowski, E. John Wherry, Matthew Adamow, Sasikanth Manne, Phillip Wong, Alexander C. Huang, Josephine R. Giles, Wei Xu, Suzanne McGettigan, Deborah Kuk, Giorgos C. Karakousis, Katherine S. Panageas, Cristina Carrera, Bertram Bengsch, Sangeeth M. George, Tara C. Gangadhar, Rosemarie Mick, Xiaowei Xu, Jedd D. Wolchok, Kristen E. Pauken, Ryan P. Staupe
Publikováno v:
Nature. 545(7652)
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical benefit. Pre-existing T-cell infiltration and/or the presence of PD-L1 in tumours may be used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f80b6f5fa1dbf1ffd0156f683ea2c381
https://pubmed.ncbi.nlm.nih.gov/28397821
https://pubmed.ncbi.nlm.nih.gov/28397821
Autor:
Irene Olorenshaw, Stefan Maas, Kenneth S. O'Rourke, Gregory A. Hawkins, Dama Laxminarayana, Robert J. Orlowski
Publikováno v:
Immunology. 125:408-419
The aetiopathogenesis of the abnormal immune response in systemic lupus erythematosus (SLE) remains incompletely understood. We and other investigators demonstrated altered expression of adenosine deaminase that act on RNA (ADAR) genes in SLE patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a319b16252ca510adf7138d4b91cf2d
https://doi.org/10.1111/j.1365-2567.2008.02850.x
https://doi.org/10.1111/j.1365-2567.2008.02850.x